Nkarta, Inc. (NASDAQ:NKTX) Insider Sells $19,003.60 in Stock

Nkarta, Inc. (NASDAQ:NKTX) insider David Shook sold 8,638 shares of Nkarta stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total value of $19,003.60. Following the sale, the insider now owns 190,955 shares in the company, valued at $420,101. The trade was a 4.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Nkarta Trading Down 0.8 %

Shares of Nkarta stock traded down $0.02 on Friday, reaching $2.47. The stock had a trading volume of 1,770,362 shares, compared to its average volume of 1,352,778. The business’s 50 day moving average is $2.54 and its two-hundred day moving average is $4.21. Nkarta, Inc. has a 1 year low of $2.08 and a 1 year high of $16.24. The company has a market cap of $174.31 million, a P/E ratio of -1.31 and a beta of 0.85.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. AQR Capital Management LLC bought a new position in shares of Nkarta in the second quarter worth $938,000. Federated Hermes Inc. grew its position in Nkarta by 28,478.7% during the second quarter. Federated Hermes Inc. now owns 135,749 shares of the company’s stock worth $802,000 after buying an additional 135,274 shares in the last quarter. Wasatch Advisors LP increased its stake in Nkarta by 31.7% in the 3rd quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock worth $8,293,000 after acquiring an additional 442,125 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Nkarta by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock valued at $5,294,000 after acquiring an additional 33,927 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Nkarta during the 2nd quarter valued at about $1,489,000. 80.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NKTX has been the topic of several research reports. Mizuho lowered their price objective on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research report on Thursday, November 21st. Needham & Company LLC dropped their price objective on Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. RODMAN&RENSHAW raised Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Rodman & Renshaw began coverage on Nkarta in a research report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price target on the stock. Finally, HC Wainwright cut their price target on Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.00.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.